相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin
Muthiah Vaduganathan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)
SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials
Nitish K. Dhingra et al.
ESC HEART FAILURE (2022)
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Volker Vallon et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 83 (2021)
SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials
Nitish K. Dhingra et al.
ESC HEART FAILURE (2021)
IGFBP7 and GDF-15, but not P1NP, are associated with cardiac alterations and 10-year outcome in an elderly community-based study
Jennifer M. T. A. Meessen et al.
BMC CARDIOVASCULAR DISORDERS (2021)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study
James L. Januzzi Jr et al.
DIABETES CARE (2021)
SGLT-2 Inhibitors and Regenerative Cell Exhaustion
David A. Hess et al.
CELL METABOLISM (2020)
Echocardiographic assessment of insulin-like growth factor binding protein-7 and early identification of acute heart failure
Arzu Kalayci et al.
ESC HEART FAILURE (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The EMPA-HEART CardioLink-6 Randomized Clinical Trial
Subodh Verma et al.
CIRCULATION (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits
Subodh Verma
AMERICAN JOURNAL OF CARDIOLOGY (2019)
Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction
Camilla Hage et al.
AMERICAN JOURNAL OF CARDIOLOGY (2018)
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma et al.
DIABETOLOGIA (2018)
IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure
James L. Januzzi et al.
CIRCULATION-HEART FAILURE (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction
Michael Coll Barroso et al.
BMC CARDIOVASCULAR DISORDERS (2016)
Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction Results From the RELAX Trial
Parul U. Gandhi et al.
JACC-HEART FAILURE (2016)
Prognostic Usefulness of Insulin-Like Growth Factor-Binding Protein 7 in Heart Failure With Reduced Ejection Fraction: A Novel Biomarker of Myocardial Diastolic Function?
Parul U. Gandhi et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
Measurement of Novel Biomarkers to Predict Chronic Heart Failure Outcomes and Left Ventricular Remodeling
Shweta R. Motiwala et al.
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH (2014)
Insulin resistance is associated with increased serum concentration of IGF-binding protein-related protein 1 (IGFBP-rP1/MAC25)
Abel Lopez-Bermejo et al.
DIABETES (2006)
分享论文
